Histogen is a regenerative medicine company with a robust product pipeline, recurrent escalating revenues from skin care sales, and a lead therapeutic product for hair growth in clinical development that addresses a multibillion dollar market worldwide. The Company has raised $26M since its inception in 2007, the majority of which has been used to develop its proprietary manufacturing process, submit worldwide patents, and advance the skin care and hair growth products.
To develop additional products without dilution to its shareholders, Histogen has formed three joint ventures: PUR Biologics, focused on the development of biologic products for orthopedic applications, Adaptive Biologix, developing a lead product for cancer applications, and Histogen Aesthetics, home of the CellCeuticals line of regenerative skin treatments.
Through a structure in which each application is supported through joint ventures, Histogen is able to minimize its burn rate and focus on developing its hair growth product, while still maintaining a strong equity position in numerous valuable therapeutic applications.
In May 2015, Histogen opened an $18M Series D financing round. This round will provide capital for development of its HSC program, including a US Phase I clinical trial in female diffuse hair loss patients and a late-stage HSC trial in male pattern hair loss, expand its manufacturing capability, other corporate purposes and to support preparation for an initial public offering (IPO).
For more information about investment opportunities please contact:
Eileen Naughton Brandt
Director of Corporate Communications